23-Apr-2021 | Market Research Store

Findings from Market Research Store report “Age Related Macular Degeneration  Market By Product Type (Dry AMD, and Wet AMD), By Drug Type (Eylea, Lucentis, Avastin, and Others), By Age Group Type (Between 40 - 50 Years, Between 50 - 60 Years, Between 60 - 70 Years, and Above 70 Years), By Route Of Administration (Intravitreal, and Intravenous), By End-User (Hospital & Clinics, Academic Research Institutes, and Diagnostic Centers): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026” states that the global demand for age related macular degeneration market in 2019 was approximately USD 8,300 Million. The market is anticipated to grow at a CAGR of 7.8% and is anticipated to reach around USD 14,100 Million by 2026.

Age-related macular degeneration (AMD), also known as macular degeneration, is a disease in which the macula of the retina thins, resulting in loss of central vision. Age-related macular degeneration is most common in the elderly population and can result in irreversible vision loss in those aged 60 and up. Dry AMD and wet age-related macular degeneration (Wet AMD) are the two forms of wet AMD and Dry AMD is the most common form of macular degeneration, in which the macula thins with age and central vision is lost. Dry age-related macular degeneration does not have a cure. The less common form of age-related macular degeneration is wet age-related macular degeneration, which is marked by the development of abnormal blood vessels under the retina. Anti-vascular endothelial growth factor (anti-VEGF) injections may be used to treat wet age-related macular degeneration.

The aging population and rising incidence of age-related macular degeneration, as well as many marketed drugs going off-patent, are expected to boost the market growth. However, factors such as the high cost of AMD and strict FDA regulations may limit market growth during the forecast period.  

The global market for age-related macular degeneration has been divided into five regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Because of the ophthalmological disorders and an aging population, North America dominates the global age-related macular degeneration market. Nearly 7.3 million people are at risk of vision loss as a result of AMD. The U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals, Inc.'s supplement Biologics License Application (sBLA) for EYLEA injection for the treatment of wet age-related macular degeneration in August 2018. (wet AMD).  Novartis' Beovu (brolucizumab) injection was approved by the US Food and Drug Administration (FDA) in October 2019 for the treatment of wet age-related macular degeneration (AMD).

Product type, medication type, age group type, route of administration, and end-user are all used to categorize age-related macular degeneration. The market is divided into dry AMD and wet AMD based on the product form. Wet AMD is caused by the formation of deposits called under the retina, while dry AMD is caused by the premature growth of blood vessels under the macula. Owing to the higher prevalence of wet AMD in the geriatric population, wet AMD has a larger market share than dry AMD. Wet macular degeneration therapies are in high demand due to the world's rising geriatric population. According to a World Health Organization (WHO) study, the number of elderly people (those aged 60 and up) will increase to 21.1 percent by 2050. The global elderly population is projected to reach 2 billion by 2050. Both of these statistics mean that medications to treat wet macular degeneration will be in high demand in the future. The market is increasing as a result of technological advancements in macular degeneration treatment and favorable payment terms. The market is divided into intravitreal and intravenous administration routes based on the path of administration. Since targeted drug distribution makes the intravitreal segment more competitive, it is expected to gain market share. Furthermore, most anti-VEGF injections are administered intravitreal or intraocularly. The market is divided into hospitals and clinics, academic research institutes, and testing centers based on end-user analysis. Hospitals and clinics are the most popular end-user group in terms of sales. This is due to a rise in the number of visits to these institutes, as well as the number of procedures performed, due to increased exposure to global developments, rising disposable incomes, and changing lifestyles, which are all common reasons for an increase in the number of visits and procedures performed. The required procedures are carried out in a sterile environment and do not require extensive waiting or recovery time. The market is divided into four age groups: 40-50 years old, 50-60 years old, 60-70 years old, and over 70 years old. According to World Population Prospects, the global population over 60 years old was 962 million in 2017 and is expected to reach around 2.1 billion by 2050. The population of people aged 60 and up is increasing faster than that of all other age groups around the world. Age-related diseases such as diabetes, renal insufficiency, asthma, and macular degeneration are especially dangerous for this group. People aged 50 to 59 have a 2% risk of developing advanced age-related macular degeneration, while people aged 75 and up have a 30% chance.

Browse the full Age Related Macular Degeneration Market By Product Type (Laser Skin Resurfacing Devices, Micro-Needling Products, Nonsurgical Skin Tightening Devices, Light Therapy Device, and Others), By Treatment Type (Laser Lipo, Body Contouring, Skin Tightening, Instant Rejuvenation, and Others), and By End-User (Medical Spas and Beauty Salons, Hospitals and Aesthetic Clinics, Home Settings, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026.” Report at https://www.marketresearchstore.com/market-insights/age-related-macular-degeneration-market-828582

Some of the key players in the market are Valeant Pharmaceuticals International, Inc., Novartis International AG, Ophthotech Corporation, Pfizer Inc., Kubota Pharmaceutical Holdings Co. Ltd, Bayer AG, Adverum Biotechnologies, Inc., Regeneron Pharmaceuticals, Inc., Amgen Inc., Gilead Sciences Inc., Apellis Pharmeceuticals, Inc., F. Hoffmann-La Roche Ltd., Bausch Health Companies Inc., Neurotech Pharmaceuticals Inc., and Alimera Sciences Inc. These international companies have used a range of tactics to achieve a credible presence in the global market, including purchasing relationships, shares, contracts, collaborations, joint ventures, new product launches, purchases, and mergers and acquisitions. Ophthotech Corporation reported in July 2017 that it will rely on clinical experience and retina skills to develop therapies for a variety of orphan ophthalmic diseases. EyeMedics, LLC and Acucela entered into an R&D partnership agreement in December 2016. F. Hoffmann-La Roche AG announced the first lampalizumab phase III trial for geographic atrophy due to AMD in September 2017.

This report segments the age related macular degeneration  market as follows:

Global Age Related Macular Degeneration  Market: By Product Type Type Segmentation Analysis:

  • Dry AMD
  • Wet AMD

Global Age Related Macular Degeneration  Market: By Drug Type Segmentation Analysis

  • Eylea
  • Lucentis
  • Avastin
  • Others

Global Age Related Macular Degeneration Market: By Age Group Type Segmentation Analysis

  • Between 40 - 50 Years
  • Between 50 - 60 Years
  • Between 60 - 70 Years
  • Above 70 Years

Global Age Related Macular Degeneration Market: By Route Of Administration Segmentation Analysis

  • Intravitreal
  • Intravenous

Global Age Related Macular Degeneration Market: By End-User Segmentation Analysis

  • Hospital & Clinics
  • Academic Research Institutes
  • Diagnostic Centers

Global Age Related Macular Degeneration Market: Regional Segmentation Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

About Us:

Market Research Store is a single destination for all types of industries, global, and regional reports. We feature large repository of latest industry reports and market statistics published by reputed private publishers and public organizations. Market Research Store is the comprehensive collection of market intelligence products and services available. Our vast database of reports enables our clients to benefit from expert insights on global industries, products, and market trends.

Contact Us:

Market Research Store
244 Fifth Avenue, Suite N202
New York, 10001, United States
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@MarketResearchStore.com
Website: https://www.marketresearchstore.com

-->